A long-acting GHRH analogue that covalently binds albumin to extend its half-life to approximately 8 days.
The Drug Affinity Complex (DAC) is a lysine side-chain modification that reacts with cysteine-34 on serum albumin after injection, creating a covalent bond. This shields the peptide from enzymatic degradation and dramatically extends its half-life, producing sustained GH and IGF-1 elevation with convenient once or twice-weekly dosing.
CJC-1295 with DAC produces a continuous elevation of GH rather than the pulsatile release seen with shorter-acting GHRHs. Some researchers prefer pulsatile GH for body composition while others prefer sustained elevation for IGF-1 optimisation.
Unlike Mod GRF (CJC no DAC), the DAC version can be administered once or twice weekly, making compliance simpler for longer research periods.